Asghar Chaudhry, MD
Nephrology · Coral Springs, FLNPI 1043244908
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Amgen at 26.8% of the total. 2025 is the largest year on record at $939, more than ten times the $19 reported in 2019.
Across 152 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$916
- AstraZeneca$588
- Travere Therapeutics, Inc.$439
- Otsuka America Pharmaceutical, Inc.$243
- ANI Pharmaceuticals, Inc.$217
- Boehringer Ingelheim$171
- plus $843 from 15 others
Across 348 payments — averaging $6018.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$946K
- CSL Behring$450K
- Akebia Therapeutics Inc$370K
- Astrazeneca UK Limited$258K
- OPKO Pharmaceuticals, LLC$26K
- Travere Therapeutics, Inc.$26K
- plus $18K from 1 others
What the payments were for
- Food & beverage$3,39599%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 53 | $916 |
| AstraZeneca | 21 | $588 |
| Travere Therapeutics, Inc. | 20 | $439 |
| Otsuka America Pharmaceutical, Inc. | 11 | $243 |
| ANI Pharmaceuticals, Inc. | 8 | $217 |
| Boehringer Ingelheim | 4 | $171 |
| Vifor Pharma, Inc. | 6 | $145 |
| Bayer | 7 | $118 |
| Sanofi | 1 | $114 |
| Aurinia Pharma U.S., Inc. | 5 | $90 |
| Novo Nordisk | 3 | $75 |
| GSK | 2 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Akebia Therapeutics Inc | 2 | $30 |
| Ardelyx, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Novartis | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,418 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 156 | $127,984 |
| KerendiaFinerenone | 102 | $84,895 |
| VelphoroSucroferric Oxyhydroxide | 21 | $43,087 |
| JardianceEmpagliflozin | 38 | $35,123 |
| AuryxiaFerric Citrate | 14 | $29,096 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $28,597 |
| LokelmaSodium Zirconium Cyclosilicate | 29 | $24,195 |
| JanuviaSitagliptin Phosphate | 11 | $10,839 |
| Cinacalcet Hcl | 13 | $4,586 |
| Sevelamer Carbonate | 27 | $3,410 |
| Valsartan | 146 | $3,174 |
| Losartan Potassium | 307 | $2,471 |
| Nifedipine ErNifedipine | 52 | $1,946 |
| Midodrine Hcl | 15 | $1,268 |
| Amlodipine Besylate | 195 | $1,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $588 | $152,179185 claims |
| BayerKerendia | $118 | $84,895102 claims |
| Fresenius USA Marketing, Inc.Velphoro | $22 | $43,08721 claims |
| Boehringer IngelheimJardiance | $171 | $35,12338 claims |
| Akebia Therapeutics IncAuryxia | $30 | $29,09614 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $217 | $3,174146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.
Other nephrology in Coral Springs
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.